A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.

Hong, Mi Jeong

A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer. [electronic resource] - Oncotarget Mar 2016 - 15948-58 p. digital

Publication Type: Journal Article

1949-2553

10.18632/oncotarget.7433 doi


Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Binding Sites
Biomarkers, Tumor--analysis
Carcinoma, Non-Small-Cell Lung--drug therapy
Cisplatin--therapeutic use
Female
Gene Expression Regulation, Neoplastic--genetics
Genotype
Humans
Kaplan-Meier Estimate
Lung Neoplasms--drug therapy
Male
MicroRNAs--genetics
Middle Aged
Paclitaxel--therapeutic use
Polymorphism, Single Nucleotide
Proto-Oncogene Protein c-ets-2--genetics